Potentiation strategies

Lithium is among the most classically recommended add-on therapeutic strategy for the management of depressive patients showing unsuccessful response to standard antidepressant medications. The effectiveness of the add-on strategy with lithium requires achieving plasma levels above 0.5 mEq/L. Mood-s...

Full description

Saved in:
Bibliographic Details
Published in:La Presse médicale (1983) 2016-03, Vol.45 (3), p.338-349
Main Authors: Doumy, Olivier, Bennabi, Djamila, El-Hage, Wissam, Allaïli, Najib, Bation, Rémy, Bellivier, Frank, Holtzmann, Jérôme, Bubrovszky, Maxime, Camus, Vincent, Charpeaud, Thomas, Courvoisier, Pierre, d'Amato, Thierry, Garnier, Marion, Haesebaert, Frédéric, Bougerol, Thierry, Lançon, Christophe, Moliere, Fanny, Nieto, Isabel, Richieri, Raphaëlle, Saba, Ghassen, Courtet, Philippe, Vaiva, Guillaume, Leboyer, Marion, Llorca, Pierre-Michel, Aouizerate, Bruno, Haffen, Emmanuel
Format: Article
Language:fre
Subjects:
Anticonvulsants - pharmacokinetics
Anticonvulsants - therapeutic use
Antidepressive Agents - classification
Antidepressive Agents - pharmacokinetics
Antidepressive Agents - therapeutic use
Antipsychotic Agents - adverse effects
Antipsychotic Agents - pharmacokinetics
Antipsychotic Agents - therapeutic use
Bipolar Disorder - drug therapy
Depressive Disorder - drug therapy
Double-Blind Method
Drug Resistance
Drug Synergism
Drug Therapy, Combination
Humans
Lithium Carbonate - pharmacokinetics
Lithium Carbonate - therapeutic use
Meta-Analysis as Topic
Practice Guidelines as Topic
Randomized Controlled Trials as Topic
Thyroid Hormones - pharmacokinetics
Thyroid Hormones - therapeutic use
Thyrotropin - blood
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lithium is among the most classically recommended add-on therapeutic strategy for the management of depressive patients showing unsuccessful response to standard antidepressant medications. The effectiveness of the add-on strategy with lithium requires achieving plasma levels above 0.5 mEq/L. Mood-stabilizing antiepileptic drugs such as carbamazepine, valproate derivatives or lamotrigine have not demonstrated conclusive therapeutic effects for the management of depressive patients showing unsuccessful response to standard antidepressant medications. Thyroid hormones are considered among the currently recommended add-on therapeutic strategy for the management of depressive patients showing unsuccessful response to standard antidepressant medications. The effectiveness of the add-on strategy with thyroid hormones requires achieving plasma concentration of TSH close to the lower limits at the normal range (0.4 μUI/L) or even below it. Second-generation antipsychotics such as aripiprazole or quetiapine have consistently demonstrated significant therapeutic effects for the management of depressive patients showing unsuccessful response to standard antidepressant medications. Second-generation antipsychotics however require the careful monitoring of both cardiovascular and metabolic adverse effects.
ISSN:2213-0276
DOI:10.1016/j.lpm.2016.02.004